Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa.

Antimicrobial agents and chemotherapy - 1 Mar 2007

Takeda Shinobu, Nakai Toru, Wakai Yoshimi, Ikeda Fumiaki, Hatano Kazuo

Abstract excerpt

FR264205 is a novel parenteral 3'-aminopyrazolium cephalosporin. This study evaluated the in vitro and in vivo activities of FR264205 against Pseudomonas aeruginosa. The MIC of FR264205 at which 90% of 193 clinical isolates of P. aeruginosa were inhibited was 1 microg/ml, 8- to 16-fold lower than those of ceftazidime (CAZ), imipenem (IPM), and ciprofloxacin (CIP). FR264205 also exhibited this level of activity...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to beta-Lactamases
Share to Burns
Share to Cephalosporins

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Lung Diseases

Share to Mice, Inbred ICR

Share to Pseudomonas aeruginosa

Share to Pseudomonas Infections

Share to Urinary Tract Infections

Source

Open in PubMed Open full text

Identifiers

PMID: 17145788
DOI: 10.1128/AAC.00860-06
PMCID: PMC1803152

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa.PMID 17145788Read ↗

Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients.Semantic proximity Read ↗

In vitro and in vivo antibacterial activities of DK-507k, a novel fluoroquinolone.Semantic proximity Read ↗

Repurposing High-Throughput Screening Identifies Unconventional Drugs with Antibacterial and Antibiofilm Activities against Pseudomonas aeruginosa under Experimental Conditions Relevant to Cystic FibrosisSemantic proximity Read ↗

Giving Drugs A Second Chance: Antibacterial and Antibiofilm Effects of Ciclopirox and Ribavirin Against Cystic Fibrosis <em>Pseudomonas Aeruginosa</em> StrainsSemantic proximity Read ↗

In vitro and in vivo evaluation of BO-2727 against imipenem- and/or meropenem-resistant Pseudomonas aeruginosa.Semantic proximity Read ↗

Activities of garenoxacin against quinolone-resistant Streptococcus pneumoniae strains in vitro and in a mouse pneumonia model.Semantic proximity Read ↗

In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.Semantic proximity Read ↗

In vitro activity of sparfloxacin (AT-4140), a new quinolone agent, against invasive isolates from pediatric patients.Semantic proximity Read ↗

Antibacterial activity of NM394, the active form of prodrug NM441, a new quinolone.Semantic proximity Read ↗

In Vitro Antibacterial Activities of JNJ-Q2, a New Broad-Spectrum FluoroquinoloneSemantic proximity Read ↗

Antimicrobial activity of DU-6681a, a parent compound of novel oral carbapenem DZ-2640.Semantic proximity Read ↗

Pharmacodynamic characterization of ceftobiprole in experimental pneumonia caused by phenotypically diverse Staphylococcus aureus strains.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.